Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Immune Checkpoint Inhibitors in Combination With Engineered Mitochondrial Vaccine as Neoadjuvant and Adjuvant Therapy for Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm, Single-Center Clinical Study.

NCT07572864 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07572864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07572864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Immune Checkpoint Inhibitors in Combination With Engineered Mitochondrial Vaccine as Neoadjuvant and Adjuvant Therapy for Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm, Single-Center Clinical Study.
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
June 29, 2026
Completion date
May 1, 2028
Enrollment
9 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma